Monte Rosa Therapeutics, Inc. · NASDAQ:GLUE
BVF PARTNERS L P/IL reported a 6.30% stake in Monte Rosa Therapeutics, Inc. (Schedule 13G/A)
Event Mar 31, 2026 · Filed May 15, 2026
BVF PARTNERS L P/IL reported a 6.30% stake in Monte Rosa Therapeutics, Inc., 5,085,886 shares, as a passive investor on Mar 31, 2026. Filed May 15, 2026 (Schedule 13G/A).
- Stake
- 6.30%
- Shares
- 5,085,886
- Intent
- Passive
- What changed
- Stake changed
- Filed together
- 10 holders
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| BIOTECHNOLOGY VALUE FUND L P | 3.40% | 2,716,569 |
| BVF I GP LLC | 3.40% | 2,716,569 |
| BIOTECHNOLOGY VALUE FUND II LP | 2.50% | 1,986,984 |
| BVF II GP LLC | 2.50% | 1,986,984 |
| Biotechnology Value Trading Fund OS LP | 0.40% | 306,361 |
| BVF Partners OS Ltd. | 0.40% | 306,361 |
| BVF GP HOLDINGS LLC | 5.80% | 4,703,553 |
| BVF PARTNERS L P/IL | 6.30% | 5,085,886 |
| BVF INC/IL | 6.30% | 5,085,886 |
| LAMPERT MARK N | 6.30% | 5,085,886 |
Source
Related
- Monte Rosa Therapeutics, Inc.
- Bvf Partners L P
- Monte Rosa Therapeutics, Inc. shareholders
- Schedule 13G/A · Bvf Partners L P · Feb 17, 2026
- Schedule 13G/A · Bvf Partners L P · May 15, 2025
- Schedule 13G · Bvf Partners L P · Jan 31, 2025
- Form 4 · Bowen Matthew · Oct 6, 2026
- Schedule 13G/A · Montanova Capital, LLC · Aug 14, 2026
- Schedule 13G · Vestal Point Capital, LP · Aug 14, 2026
- Form 4 · Warmuth Markus · Jul 17, 2026
- Form 4 · Champoux Jennifer · Jul 16, 2026